Switching to long-acting HIV shots after jail release
Part of Immune system & allergy, Infections, Mental health clinical trials.
This study offers people leaving jail in Baltimore a switch from daily HIV pills to long-acting shots given every 1–2 months at community clinics. The goal is to make it easier to keep HIV under control after release.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can speak English.
- You are living with HIV and currently taking HIV medications in pill form.
- Your HIV viral load (amount of virus in the blood) has been undetectable for at least 3 months before joining.
- You are expected to be released from a Maryland correctional facility within about 3 months.
- You plan to live in the Baltimore City area after release and are willing to get HIV medication injections at community clinics instead of taking daily pills.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study helps men recently released from jail who inject drugs to start and stay on PrEP, a daily medicine that prevents HIV. The goal is to support them in taking PrEP regularly and staying connected to care.
This study provides legal support to improve HIV care for people who have recently been released from jail or prison. It helps them stay in treatment and lower their viral load.
This study helps people with HIV or high risk of HIV who have had substance use problems and are in jail or recently released. It tests a program called SUCCESS-E to support health and reduce drug use.
This study tests a better way to start long-acting HIV prevention (PrEP) and buprenorphine for opioid use disorder while people are in jail, to see if it helps them stay healthy after release. If you are soon leaving jail and have opioid use disorder, you may be able to join.
This trial tests whether switching from daily HIV pills to a long-acting injectable combination (cabotegravir and rilpivirine) is safe and effective for people whose HIV is well controlled. Instead of taking pills every day, you would receive a shot every month or two, which may be more convenient.
This study tests whether a pharmacist can safely give long-acting HIV medications every 4 or 8 weeks. It aims to help more people with HIV get this treatment easily.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.